Encouraging results reported from trial of Merck AIDS vaccine

Results from clinical tests of a Merck AIDS vaccine have been better than expected, prompting the researchers to double enrollment in the trial to 3,000 participants. The study is examining healthy volunteers to determine their immune response to the vaccine, and the trial later may indicate whether the immune reactions can prevent or control AIDS.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA